Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer. In this post, I will discuss our most recent understanding of this aggressive disease.

almost all women with IBC have lymph node involvement at the time of diagnosis.

Continue reading “Inflammatory Breast Cancer”

Prognostic Signatures in Breast Cancer

Prognostic signatures are also known as Gene Expression Profiles (GEP) are now commonly used in the clinic to stratify hormone positive breast cancer patients risk of distant recurrence at 10 years and aid treatment strategy decision making. In this blog post, I will review the commonly used GEP and hopefully illustrate their proper clinical utilization as well as limitations. In a previous post, I discussed the adjuvant endocrine therapy for hormone positive breast cancer, for details please click here.

The use of GEP in Early stage breast cancer signficantly reduced the use of Chemotherapy in this patient population.

Continue reading “Prognostic Signatures in Breast Cancer”

Another PARP inhibitor showing promise

PARP inhibitors are unique molecules targeting only the PARP enzyme in BRCA 1/2 mutated cells, they are generally well tolerated as compared to chemotherapy. In this year at San Antonio Breast Cancer Symposium, the EMBRACA trial results were presented in abstract form.

The talazoparib arm patients reported better quality of life score as well as there was a significant delay in the time to deterioration

 

Continue reading “Another PARP inhibitor showing promise”

Adjuvant Capecitabine the CREAT-X trial

CREAT-X, Capcetabine for Residual Cancer as Adjuvant Therapy trial is the first of it’s kind to look into further adjuvant chemotherapy in patients who received neoadjuvant chemotherapy.

Capecitabine adjuvant therapy is beneficial in Her2-negative Breast cancer with residual disease following Neoadjuvant therapy.

 

Continue reading “Adjuvant Capecitabine the CREAT-X trial”